<p>2025 年 08 月 08 日- 下午 09:05</p>
<p><strong>安必欧在应对蚊媒传播疾病和新兴呼吸道病原体方面，持续推进即时检测技术，以便在全球范围内及时发现疫情。</strong></p>
<p>德国法兰克福，2025 年 8 月 8 日（GLOBE NEWSWIRE）-- 针对近期的基孔肯雅热疫情，安必欧生物科技宣布推出基孔肯雅 IgM/IgG 快速检测，向临床医生和公共卫生部门提供一种快速、可及的即时检测工具。随着热带和亚热带地区病例的持续上升，及时检测和与登革热、寨卡等其他虫媒病毒感染的区分变得至关重要。</p>
<p>该检测基于免疫层析技术，能够可靠地定性检测人类血清、血浆或全血中的基孔肯雅特异性抗体。这一新增检测增强了安必欧的传染病诊断产品组合，并支持公共卫生部门应对新兴疫情的努力。</p>
<p>与此同时，安必欧正在推进分散式分子诊断的边界，推出其新的 AP-100 超快速 PCR 系统，旨在将实验室级别的检测能力直接带到即时检测现场。</p>
<p>“疫情需要速度。AP-100 将传统 PCR 的几个小时缩短为几分钟，而不影响准确性，” 安必欧生物科技首席执行官 Michael Lau 表示。</p>
<p>AP-100 利用先进的微流体热循环系统，结合高效的酶放大化学，能够直接处理拭子样本，无需核酸提取。其集成设计简化了样本到结果的工作流程，使其非常适合在集中实验室和分散的即时检测环境中部署。</p>
<p>主要亮点：</p>
<ul>
<li>从原始样本到结果仅需 15 分钟的 PCR 结果</li>
<li>无需提取的工作流程，无有害试剂</li>
<li>重量仅 668 克的紧凑设备，适合移动或近患者检测</li>
<li>广泛的病原体覆盖，包括 COVID-19、流感 A/B、RSV、MP 和 ADV</li>
<li>与主流 PCR 平台验证的实验室可比准确性</li>
</ul>
<p>虽然最初专注于呼吸道感染，AP-100 被设计为一个灵活的分子平台。根据其全球传染病战略，安必欧正在扩展检测组合，包括结核病（TB）和人乳头瘤病毒（HPV）的检测，将其角色从快速疫情响应扩展到持续的疾病管理。</p>
<p>“无论是虫媒传播的发热还是呼吸道大流行，我们相信诊断应与威胁的速度相匹配，” Lau 补充道。</p>
<p>凭借速度、移动性和实验室级精确度的结合，安必欧的新一代 POCT PCR 系统增强了在资源丰富和资源有限环境中的医疗能力，提升了全球应对传染病威胁的准备能力。</p>
<p><strong>关于安必欧生物科技</strong></p>
<p>安必欧生物科技是一家全球导向的体外诊断（IVD）公司，提供广泛的解决方案，包括免疫荧光、干化学、化学发光、分子诊断、快速检测和兽医诊断。公司在多个地区开展业务，致力于提高可靠和及时的诊断的可用性，支持全球医疗环境中的更好决策。</p>
<p>有关安必欧生物科技的更多信息，请关注我们以获取最新消息和更新。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09UUXhNQ00zTURnNU56WTJJekl6TURBd09Uaz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09UUXhNQ00zTURnNU56WTJJekl6TURBd09Uaz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2VhNGI3NGUtMzgwMy00N2NmLWIyZWItNDc1YTExYTViOGEyLTEzMTE2NDktMjAyNS0wOC0wOS1lbg==/tiny/Anbio-Biotechnology.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2VhNGI3NGUtMzgwMy00N2NmLWIyZWItNDc1YTExYTViOGEyLTEzMTE2NDktMjAyNS0wOC0wOS1lbg==/tiny/Anbio-Biotechnology.png"/></p>
<pre><code> 联系方式: connect@anbio.info
</code></pre>

NNNN

<p>安比奥生物科技推出了基孔肯雅病毒 IgM/IgG 快速检测和 AP-100 超快速 PCR 系统，以增强疫情检测和响应能力。该快速检测为基孔肯雅热提供了快速诊断，这对于与登革热和寨卡病毒等其他感染的区分至关重要。AP-100 在仅 15 分钟内提供实验室级别的 PCR 结果，简化了集中和现场检测的工作流程。安比奥旨在通过这些创新改善全球健康准备，扩展其诊断能力，包括结核病和人乳头瘤病毒的检测</p>

<p>08/08/2025 - 09:05 PM</p>
<div class="lb-trans"><p>2025 年 08 月 08 日- 下午 09:05</p>
</div><p><strong>Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.</strong></p>
<div class="lb-trans"><p><strong>安必欧在应对蚊媒传播疾病和新兴呼吸道病原体方面，持续推进即时检测技术，以便在全球范围内及时发现疫情。</strong></p>
</div><p>FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical.</p>
<div class="lb-trans"><p>德国法兰克福，2025 年 8 月 8 日（GLOBE NEWSWIRE）-- 针对近期的基孔肯雅热疫情，安必欧生物科技宣布推出基孔肯雅 IgM/IgG 快速检测，向临床医生和公共卫生部门提供一种快速、可及的即时检测工具。随着热带和亚热带地区病例的持续上升，及时检测和与登革热、寨卡等其他虫媒病毒感染的区分变得至关重要。</p>
</div><p>The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio’s infectious disease diagnostics portfolio and supports public health efforts in responding to emerging outbreaks.</p>
<div class="lb-trans"><p>该检测基于免疫层析技术，能够可靠地定性检测人类血清、血浆或全血中的基孔肯雅特异性抗体。这一新增检测增强了安必欧的传染病诊断产品组合，并支持公共卫生部门应对新兴疫情的努力。</p>
</div><p>In parallel, Anbio is advancing the boundaries of decentralized molecular diagnostics with the launch of its new AP-100 Ultra-Fast PCR system, designed to bring laboratory-grade testing capabilities directly to the point of care.</p>
<div class="lb-trans"><p>与此同时，安必欧正在推进分散式分子诊断的边界，推出其新的 AP-100 超快速 PCR 系统，旨在将实验室级别的检测能力直接带到即时检测现场。</p>
</div><p>“Outbreaks demand speed. The AP-100 collapses hours of traditional PCR into minutes, without compromising accuracy,” said Michael Lau, CEO of Anbio Biotechnology.</p>
<div class="lb-trans"><p>“疫情需要速度。AP-100 将传统 PCR 的几个小时缩短为几分钟，而不影响准确性，” 安必欧生物科技首席执行官 Michael Lau 表示。</p>
</div><p>The AP-100 utilizes an advanced microfluidic thermal cycling system combined with high-efficiency enzymatic amplification chemistry, enabling direct processing of swab samples without the need for nucleic acid extraction. Its integrated design streamlines sample-to-result workflows, making it well-suited for deployment in both centralized laboratories and decentralized, point-of-care environments.</p>
<div class="lb-trans"><p>AP-100 利用先进的微流体热循环系统，结合高效的酶放大化学，能够直接处理拭子样本，无需核酸提取。其集成设计简化了样本到结果的工作流程，使其非常适合在集中实验室和分散的即时检测环境中部署。</p>
</div><p>Key highlights:</p>
<div class="lb-trans"><p>主要亮点：</p>
</div><ul>
<li>15-minute PCR results from raw sample to answer</li>
<li>Extraction-free workflow with no hazardous reagents</li>
<li>Compact 668g device for mobile or near-patient testing</li>
<li>Broad pathogen coverage, including COVID-19, Flu A/B, RSV, MP, and ADV</li>
<li>Lab-comparable accuracy validated against mainstream PCR platforms</li>
</ul>
<div class="lb-trans"><ul>
<li>从原始样本到结果仅需 15 分钟的 PCR 结果</li>
<li>无需提取的工作流程，无有害试剂</li>
<li>重量仅 668 克的紧凑设备，适合移动或近患者检测</li>
<li>广泛的病原体覆盖，包括 COVID-19、流感 A/B、RSV、MP 和 ADV</li>
<li>与主流 PCR 平台验证的实验室可比准确性</li>
</ul>
</div><p>While initially focused on respiratory infections, the AP-100 is designed as a flexible molecular platform. In line with its global infectious disease strategy, Anbio is expanding the assay portfolio to include tests for tuberculosis (TB) and human papillomavirus (HPV), extending its role from rapid outbreak response to sustained disease management.</p>
<div class="lb-trans"><p>虽然最初专注于呼吸道感染，AP-100 被设计为一个灵活的分子平台。根据其全球传染病战略，安必欧正在扩展检测组合，包括结核病（TB）和人乳头瘤病毒（HPV）的检测，将其角色从快速疫情响应扩展到持续的疾病管理。</p>
</div><p>“Whether it’s vector-borne fevers or respiratory pandemics, we believe diagnostics should move as fast as the threat,” Lau added.</p>
<div class="lb-trans"><p>“无论是虫媒传播的发热还是呼吸道大流行，我们相信诊断应与威胁的速度相匹配，” Lau 补充道。</p>
</div><p>With its combination of speed, mobility, and lab-grade precision, Anbio’s new-generation POCT PCR system strengthens healthcare capacity in both well-resourced and resource-limited settings, advancing global preparedness for infectious disease threats.</p>
<div class="lb-trans"><p>凭借速度、移动性和实验室级精确度的结合，安必欧的新一代 POCT PCR 系统增强了在资源丰富和资源有限环境中的医疗能力，提升了全球应对传染病威胁的准备能力。</p>
</div><p><strong>About Anbio Biotechnology</strong></p>
<div class="lb-trans"><p><strong>关于安必欧生物科技</strong></p>
</div><p>Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics. With operations across multiple regions, the company works to enhance the availability of reliable and timely diagnostics, supporting better decision-making in healthcare settings worldwide.</p>
<div class="lb-trans"><p>安必欧生物科技是一家全球导向的体外诊断（IVD）公司，提供广泛的解决方案，包括免疫荧光、干化学、化学发光、分子诊断、快速检测和兽医诊断。公司在多个地区开展业务，致力于提高可靠和及时的诊断的可用性，支持全球医疗环境中的更好决策。</p>
</div><p>For more information about Anbio Biotechnology, follow us for the latest news and updates.</p>
<div class="lb-trans"><p>有关安必欧生物科技的更多信息，请关注我们以获取最新消息和更新。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09UUXhNQ00zTURnNU56WTJJekl6TURBd09Uaz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTUwOTQxMCM3MDg5NzY2IzIzMDAwOTk="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2VhNGI3NGUtMzgwMy00N2NmLWIyZWItNDc1YTExYTViOGEyLTEzMTE2NDktMjAyNS0wOC0wOS1lbg==/tiny/Anbio-Biotechnology.png" alt="" original-src="https://ml.globenewswire.com/media/M2VhNGI3NGUtMzgwMy00N2NmLWIyZWItNDc1YTExYTViOGEyLTEzMTE2NDktMjAyNS0wOC0wOS1lbg==/tiny/Anbio-Biotechnology.png"/></p>
<pre><code>Contact:connect@anbio.info
</code></pre>
<div class="lb-trans"><pre><code> 联系方式: connect@anbio.info
</code></pre>
</div>

安必生物技术公司推出基孔肯雅快速检测和新的 15 分钟超快 PCR 系统，以应对全球疫情 | NNNN 股票新闻